Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Naomi Balzer Haas, Judith B. Manola, Robert G. Uzzo et al. · The Lancet · 2016
Cited by 630 works. doi:10.1016/s0140-6736(16)00559-6
Authors
- Naomi Balzer Haas
- Judith B. Manola
- Robert G. Uzzo
- Keith T. Flaherty
- Christopher G. Wood
- Christopher J. Kane
- Michael A.S. Jewett
- Janice P. Dutcher
- Michael B. Atkins
- Michael Pins
- George Wilding
- David F Cella
- Lynne I. Wagner
- Surena F. Matin
- Timothy Michael Kuzel
- Wade Jeffers Sexton
- Yu‐Ning Wong
- Toni K. Choueiri
- Роберто Пили
- Igor J. Puzanov
References
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- Mutations of the VHL tumour suppressor gene in renal carcinoma
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis